0.3579
Precedente Chiudi:
$0.3559
Aprire:
$0.364
Volume 24 ore:
2.75M
Relative Volume:
0.38
Capitalizzazione di mercato:
$52.47M
Reddito:
$49.09M
Utile/perdita netta:
$-52.15M
Rapporto P/E:
-0.5506
EPS:
-0.65
Flusso di cassa netto:
$-45.93M
1 W Prestazione:
+18.84%
1M Prestazione:
-27.72%
6M Prestazione:
-72.04%
1 anno Prestazione:
-74.61%
Biodesix Inc Stock (BDSX) Company Profile
Nome
Biodesix Inc
Settore
Industria
Telefono
303-417-0500
Indirizzo
919 WEST DILLON ROAD, LOUISVILLE
Confronta BDSX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BDSX
Biodesix Inc
|
0.358 | 32.24M | 49.09M | -52.15M | -45.93M | -0.65 |
![]()
TMO
Thermo Fisher Scientific Inc
|
393.90 | 152.86B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
184.97 | 136.66B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
499.86 | 41.18B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
108.29 | 32.05B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IQV
Iqvia Holdings Inc
|
136.51 | 24.29B | 15.50B | 1.33B | 2.16B | 7.34 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-14 | Downgrade | William Blair | Outperform → Mkt Perform |
2024-09-16 | Iniziato | Scotiabank | Sector Outperform |
2024-07-26 | Iniziato | Craig Hallum | Buy |
2024-05-13 | Iniziato | TD Cowen | Buy |
2024-05-03 | Iniziato | Lake Street | Buy |
2021-11-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2020-11-23 | Iniziato | BTIG Research | Buy |
2020-11-23 | Iniziato | Canaccord Genuity | Buy |
2020-11-23 | Iniziato | Morgan Stanley | Overweight |
2020-11-23 | Iniziato | William Blair | Outperform |
Mostra tutto
Biodesix Inc Borsa (BDSX) Ultime notizie
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting | BDSX Stock News - GuruFocus
Biodesix to Present New Data on Host Immune Classifier for NSCLC at 2025 ASCO Annual Meeting - Nasdaq
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting - GlobeNewswire
Game-Changing Cancer Test Triples Survival Rate: New Clinical Data Transforms Lung Cancer Treatment - Stock Titan
Biodesix (BDSX) Target Price Reduced to $2 by Scotiabank | BDSX Stock News - GuruFocus
Biodesix Jumps 46% As Insider Buying, Retail Optimism Offset Scotiabank Target Cut By Stocktwits - Investing.com India
Scotiabank cuts Biodesix stock target to $2, maintains outlook By Investing.com - Investing.com Canada
Biodesix Approves Reverse Stock Split at Annual Meeting - TipRanks
Scotiabank cuts Biodesix stock target to $2, maintains outlook - Investing.com
Biodesix (BDSX) Sees Target Price Lowered by Scotiabank | BDSX S - GuruFocus
Biodesix to Participate in Upcoming Investor Conferences | BDSX Stock News - GuruFocus
Biodesix to Participate in Upcoming Investor Conferences - GlobeNewswire
Biodesix Executives Set for Major Investor Conferences: William Blair and Craig-Hallum Presentations Ahead - Stock Titan
Director’s Massive Stock Purchase Signals Confidence in Biodesix! - TipRanks
Biodesix's (BDSX) "Market Perform" Rating Reaffirmed at William Blair - MarketBeat
Craig Hallum Cuts Biodesix (NASDAQ:BDSX) Price Target to $1.50 - Defense World
Biodesix revises 2025 revenue guidance to $80M–$85M amid sales force reconfiguration and primary care expansion - MSN
Susquehanna International Group LLP Grows Stock Holdings in Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
Biodesix, Inc. (NASDAQ:BDSX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
Biodesix, Inc. Earnings Call: Growth Amid Challenges - TipRanks
Biodesix, Inc. (NASDAQ:BDSX) Q1 2025 Earnings Call Transcript - MSN
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers - simplywall.st
Biodesix Announces New Clinical and Economic Data for Its Nodify Lung® Tests At ISPOR and ATS - marketscreener.com
News Flash: 6 Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Earnings Are Under Threat - Yahoo Finance
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS | BDSX Stock News - GuruFocus
Biodesix, Inc. to Present New Data on Lung Cancer Diagnosis and Testing at ISPOR and ATS 2025 Conferences - Nasdaq
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS - GlobeNewswire
New Clinical Data: Biodesix Lung Cancer Tests Could Prevent 60% of Unnecessary Invasive Procedures - Stock Titan
Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award - GlobeNewswire
Biodesix Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Craig-Hallum Adjusts Price Target for Biodesix (BDSX) | BDSX Sto - GuruFocus
Diagnostic Leader Biodesix Clinches Elite Colorado Workplace Award, Employee Survey Reveals Why - Stock Titan
Biodesix stock plunges as life-sciences firm cuts sales projection - BizWest
Biodesix (BDSX): Analyst Maintains Buy Rating Despite Lowered Pr - GuruFocus
Biodesix (BDSX) Target Price Lowered by Lake Street Analyst | BD - GuruFocus
Canaccord cuts Biodesix stock target to $1.50, keeps buy rating By Investing.com - Investing.com Nigeria
Biodesix stock target cut to $2 by TD Cowen, retains buy rating - Investing.com
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates - MSN
Biodesix (BDSX) Target Price Lowered by Lake Street Analyst | BDSX Stock News - GuruFocus
Biodesix Inc Reports Q1 2025 Earnings: EPS of -$0.08 Misses Esti - GuruFocus
Biodesix stock rating cut to Market Perform at William Blair By Investing.com - Investing.com South Africa
BDSX: Canaccord Genuity Lowers Price Target for Biodesix | BDSX Stock News - GuruFocus
Canaccord cuts Biodesix stock target to $1.50, keeps buy rating - Investing.com Australia
BDSX Reports Q1 Revenue Below Expectations, Highlights Strategic - GuruFocus
Biodesix price target lowered to $1.50 from $2.50 at Canaccord - TipRanks
Biodesix (BDSX) Price Target Reduced as 2025 Revenue Outlook Dec - GuruFocus
Biodesix price target lowered to $1.50 from $3 at Craig-Hallum - TipRanks
Biodesix price target lowered to $2 from $3 at TD Cowen - TipRanks
Biodesix (BDSX) Downgraded to Market Perform by William Blair | - GuruFocus
Biodesix (BDSX) Target Price Reduced to $2 Amid Revenue Challeng - GuruFocus
Biodesix (BDSX) Price Target Reduced as 2025 Revenue Outlook Declines | BDSX Stock News - GuruFocus
Biodesix Inc Azioni (BDSX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):